| References |
Top |
| REF 1 |
Proteomic dissection of the von Hippel-Lindau (VHL) interactome. J Proteome Res. 2011 Nov 4;10(11):5175-82.
|
| REF 2 |
The interaction of the von Hippel-Lindau tumor suppressor and heterochromatin protein 1. Arch Biochem Biophys. 2012 Feb 15;518(2):103-10.
|
| REF 3 |
VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev. 2004 Dec 15;18(24):3055-65.
|
| REF 4 |
Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol Syst Biol. 2007;3:89.
|
| REF 5 |
The von Hippel-Lindau tumor suppressor regulates programmed cell death 5-mediated degradation of Mdm2. Oncogene. 2015 Feb 5;34(6):771-9.
|
| REF 6 |
ASB proteins interact with Cullin5 and Rbx2 to form E3 ubiquitin ligase complexes. FEBS Lett. 2005 Dec 19;579(30):6796-802.
|
| REF 7 |
DCNL1 functions as a substrate sensor and activator of cullin 2-RING ligase. Mol Cell Biol. 2013 Apr;33(8):1621-31.
|
| REF 8 |
An ID2-dependent mechanism for VHL inactivation in cancer. Nature. 2016 Jan 14;529(7585):172-7.
|
| REF 9 |
A molecular basis for stabilization of the von Hippel-Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase. J Biol Chem. 2002 Aug 16;277(33):30388-93.
|
| REF 10 |
von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2706-11.
|
| REF 11 |
Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions. Oncogene. 2006 Jan 19;25(3):370-7.
|
| REF 12 |
Analysis of Nedd8-associated polypeptides: a model for deciphering the pathway for ubiquitin-like modifications. Biochemistry. 2006 Mar 7;45(9):3014-9.
|
| REF 13 |
PIAS4 is an activator of hypoxia signalling via VHL suppression during growth of pancreatic cancer cells. Br J Cancer. 2013 Oct 1;109(7):1795-804.
|
| REF 14 |
Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification. PLoS One. 2010 Mar 16;5(3):e9720.
|
| REF 15 |
pVHL-mediated transcriptional repression of c-Myc by recruitment of histone deacetylases. Mol Cells. 2012 Feb;33(2):195-201.
|
| REF 16 |
FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001 Oct 15;15(20):2675-86.
|
| REF 17 |
Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6459-63.
|
| REF 18 |
Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein. Sci Rep. 2015 Jul 27;5:12605.
|
| REF 19 |
Architecture of the human interactome defines protein communities and disease networks. Nature. 2017 May 25;545(7655):505-509.
|
| REF 20 |
Interaction of hydroxylated collagen IV with the von hippel-lindau tumor suppressor. J Biol Chem. 2007 May 4;282(18):13264-9.
|
| REF 21 |
Characterization of Cullin-box sequences that direct recruitment of Cul2-Rbx1 and Cul5-Rbx2 modules to Elongin BC-based ubiquitin ligases. J Biol Chem. 2008 Mar 21;283(12):8005-13.
|
| REF 22 |
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2156-61.
|
| REF 23 |
Interaction between von Hippel-Lindau Protein and Fatty Acid Synthase Modulates Hypoxia Target Gene Expression. Sci Rep. 2017 Aug 3;7(1):7190.
|
| REF 24 |
Substrate-mediated regulation of cullin neddylation. J Biol Chem. 2007 Jun 8;282(23):17032-40.
|
| REF 25 |
Oxygen-independent degradation of HIF-alpha via bioengineered VHL tumour suppressor complex. EMBO Mol Med. 2009 Apr;1(1):66-78.
|
| REF 26 |
Role of the NEDD8 modification of Cul2 in the sequential activation of ECV complex. Neoplasia. 2006 Nov;8(11):956-63.
|
| REF 27 |
NEDD8 acts as a 'molecular switch' defining the functional selectivity of VHL. EMBO Rep. 2008 May;9(5):486-91.
|
| REF 28 |
Dynamic HIF1A regulation during human placental development. Biol Reprod. 2006 Jul;75(1):112-21.
|
| REF 29 |
Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Mol Cell Biol. 2002 Mar;22(6):1947-60.
|
| REF 30 |
Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J Clin Invest. 1999 Dec;104(11):1583-91.
|
| REF 31 |
The von Hippel-Lindau tumor suppressor protein and Egl-9-Type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress. Mol Cell Biol. 2008 Apr;28(8):2701-17.
|
| REF 32 |
Identification of pVHL as a novel substrate for Aurora-A in clear cell renal cell carcinoma (ccRCC). PLoS One. 2013 Jun 13;8(6):e67071.
|
| REF 33 |
Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL. Oncogene. 2017 Jun 15;36(24):3450-3463.
|
| REF 34 |
Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain. J Biol Chem. 2005 Jun 10;280(23):22205-11.
|
| REF 35 |
Von Hippel-Lindau regulates interleukin-32 stability in ovarian cancer cells. Oncotarget. 2017 Jul 17;8(41):69833-69846.
|
| REF 36 |
The von Hippel-Lindau tumour-suppressor protein interaction with protein kinase Cdelta. Biochem J. 2006 Jul 1;397(1):109-20.
|
| REF 37 |
The von Hippel-Lindau protein pVHL inhibits ribosome biogenesis and protein synthesis. J Biol Chem. 2013 Jun 7;288(23):16588-97.
|
| REF 38 |
Regulation of the transcriptional activation of the androgen receptor by the UXT-binding protein VHL. Biochem J. 2013 Nov 15;456(1):55-66.
|
| REF 39 |
The von hippel-lindau protein suppresses androgen receptor activity. Mol Endocrinol. 2014 Feb;28(2):239-48.
|
| REF 40 |
The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity. Nat Cell Biol. 2012 Jan 29;14(2):201-8.
|
| REF 41 |
RHOBTB3 promotes proteasomal degradation of HIF through facilitating hydroxylation and suppresses the Warburg effect. Cell Res. 2015 Sep;25(9):1025-42.
|
| REF 42 |
Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2002 Feb 15;277(7):4656-62.
|
| REF 43 |
Deubiquitinating enzyme USP33/VDU1 is required for Slit signaling in inhibiting breast cancer cell migration. Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14530-5.
|
| REF 44 |
p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell. 2006 May 5;22(3):395-405.
|
| REF 45 |
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999 May 20;399(6733):271-5.
|
| REF 46 |
pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. Science. 2016 Aug 26;353(6302):929-32.
|
| REF 47 |
von Hippel-Lindau protein adjusts oxygen sensing of the FIH asparaginyl hydroxylase. Int J Biochem Cell Biol. 2011 May;43(5):795-804.
|
| REF 48 |
Phospholipase D1 protein coordinates dynamic assembly of HIF-1-PHD-VHL to regulate HIF-1 stability. Oncotarget. 2014 Dec 15;5(23):11857-72.
|
| REF 49 |
Phospholipase D2 promotes degradation of hypoxia-inducible factor-1 independent of lipase activity. Exp Mol Med. 2015 Nov 27;47:e196.
|
| REF 50 |
COMMD1 disrupts HIF-1alpha/beta dimerization and inhibits human tumor cell invasion. J Clin Invest. 2010 Jun;120(6):2119-30.
|
| REF 51 |
Role of the C-terminal alpha-helical domain of the von Hippel-Lindau protein in its E3 ubiquitin ligase activity. Oncogene. 2004 Mar 25;23(13):2315-23.
|
| REF 52 |
Spermidine/spermine-N1-acetyltransferase 2 is an essential component of the ubiquitin ligase complex that regulates hypoxia-inducible factor 1alpha. J Biol Chem. 2007 Aug 10;282(32):23572-80.
|
| REF 53 |
STAT3 inhibits the degradation of HIF-1alpha by pVHL-mediated ubiquitination. Exp Mol Med. 2008 Oct 31;40(5):479-85.
|
| REF 54 |
Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10430-5.
|
| REF 55 |
Loss of Mel-18 induces tumor angiogenesis through enhancing the activity and expression of HIF-1 mediated by the PTEN/PI3K/Akt pathway. Oncogene. 2011 Nov 10;30(45):4578-89.
|
| REF 56 |
Reciprocal regulation of HIF-1 and lincRNA-p21 modulates the Warburg effect. Mol Cell. 2014 Jan 9;53(1):88-100.
|
| REF 57 |
Proteostasis modulators prolong missense VHL protein activity and halt tumor progression. Cell Rep. 2013 Jan 31;3(1):52-9.
|
| REF 58 |
VDUP1 mediates nuclear export of HIF1alpha via CRM1-dependent pathway. Biochim Biophys Acta. 2008 May;1783(5):838-48.
|
| REF 59 |
HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9630-5.
|
| REF 60 |
Cancer-causing mutations in a novel transcription-dependent nuclear export motif of VHL abrogate oxygen-dependent degradation of hypoxia-inducible factor. Mol Cell Biol. 2008 Jan;28(1):302-14.
|
| REF 61 |
Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2000 Aug 18;275(33):25733-41.
|
| REF 62 |
Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex. J Biol Chem. 2005 Mar 4;280(9):7985-96.
|
| REF 63 |
Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Nat Med. 2011 Jun 19;17(7):845-53.
|
| REF 64 |
Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet. 2001 May 1;10(10):1029-38.
|
| REF 65 |
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001 Apr 20;292(5516):464-8.
|
| REF 66 |
RSUME inhibits VHL and regulates its tumor suppressor function. Oncogene. 2015 Sep 10;34(37):4855-66.
|
| REF 67 |
A yeast two-hybrid system reconstituting substrate recognition of the von Hippel-Lindau tumor suppressor protein. Nucleic Acids Res. 2007;35(21):e142.
|
| REF 68 |
Tumor suppressor von Hippel-Lindau (VHL) stabilization of Jade-1 protein occurs through plant homeodomains and is VHL mutation dependent. Cancer Res. 2004 Feb 15;64(4):1278-86.
|
| REF 69 |
The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1. J Biol Chem. 2002 Oct 18;277(42):39887-98.
|
| REF 70 |
TCTP increases stability of hypoxia-inducible factor 1 by interaction with and degradation of the tumour suppressor VHL. Biol Cell. 2013 May;105(5):208-218.
|
| REF 71 |
The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 1999 Jul 15;13(14):1822-33.
|
| REF 72 |
VBP1 represses cancer metastasis by enhancing HIF-1 degradation induced by pVHL. FEBS J. 2018 Jan;285(1):115-126.
|
| REF 73 |
Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness. Oncogene. 2011 Feb 3;30(5):535-47.
|
| REF 74 |
VHL type 2B mutations retain VBC complex form and function. PLoS One. 2008;3(11):e3801.
|
| REF 75 |
pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol. 2004 Apr;24(8):3251-61.
|
| REF 76 |
Association of SAP130/SF3b-3 with Cullin-RING ubiquitin ligase complexes and its regulation by the COP9 signalosome. BMC Biochem. 2008 Jan 3;9:1.
|
| REF 77 |
The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell. 1998 Jun;1(7):959-68.
|
| REF 78 |
Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2. Oncogene. 2008 Feb 7;27(7):1004-12.
|
| REF 79 |
Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2001 Jan 12;276(2):1407-16.
|
| REF 80 |
pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11661-6.
|
| REF 81 |
Downregulation of integrins by von Hippel-Lindau (VHL) tumor suppressor protein is independent of VHL-directed hypoxia-inducible factor alpha degradation. Biochem Cell Biol. 2008 Jun;86(3):227-34.
|
| REF 82 |
Association of the von Hippel-Lindau protein with AUF1 and posttranscriptional regulation of VEGFA mRNA. Mol Cancer Res. 2012 Jan;10(1):108-20.
|
| REF 83 |
Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product. Cancer Res. 1996 Jul 1;56(13):2881-5.
|
| REF 84 |
Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma. Oncogene. 2005 Nov 24;24(53):7850-8.
|
| REF 85 |
The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene. 2007 Oct 4;26(45):6499-508.
|
| REF 86 |
Tid-1 interacts with the von Hippel-Lindau protein and modulates angiogenesis by destabilization of HIF-1alpha. Cancer Res. 2005 Apr 1;65(7):2520-5.
|
| REF 87 |
The HILDA complex coordinates a conditional switch in the 3'-untranslated region of the VEGFA mRNA. PLoS Biol. 2013;11(8):e1001635.
|
| REF 88 |
A novel VHL isoform inhibits Warburg effect via modulation of PKM splicing. Tumour Biol. 2016 Oct;37(10):13649-13657.
|
| REF 89 |
Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol. 2003 Jan;5(1):64-70.
|
